Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13325 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Yosuke Inukai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hypertension, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objectives
To identify the diagnostic criteria for metabolic dysfunction–associated steatotic liver disease (MASLD) related to liver fibrosis and to characterize patients with cryptogenic steatotic liver disease (SLD) (non‐MASLD) among those previously diagnosed with nonalcoholic fatty liver disease (NAFLD).
Methods
This multicenter retrospective study included 511 patients diagnosed with NAFLD via liver biopsy, and the prevalence of MASLD was assessed based on the diagnostic criteria. Patients were divided into those who met the MASLD criteria and those who did not, and the characteristics of advanced fibrosis and associated cardiometabolic factors were evaluated.
Results
Of the 475 patients with NAFLD, 458 (96.4%) met the criteria for MASLD, showing a high overlap between classical NAFLD and MASLD populations. Severe fibrosis was observed, regardless of the number of cardiometabolic factors. Hypertension and diabetes mellitus significantly contributed to advanced fibrosis (≥ F3), with odds ratio of 1.92 and 2.00 (95% confidence interval of 1.17–3.16 and 1.22–3.28, respectively; both p < 0.01) on multivariate analysis. The other seventeen (3.6%) patients did not meet the diagnostic criteria for MASLD. Among them, seven had significant fibrosis and a high fibrosis‐4 index.
Conclusions
Diabetes mellitus and hypertension are key metabolic factors associated with advanced fibrosis. Some cases, classified as cryptogenic SLD, also exhibit significant fibrosis. Consequently, identifying high‐risk patients, including those undergoing noninvasive tests for fibrosis, is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Gastroenterology, Japan Community Health Care Organization Kani Tono Hospital, Kani, Japan.
- Department of Gastroenterology, Yamashita Hospital, Ichinomiya, Japan.
- Department of Gastroenterology, Nishichita General Hospital, Tokai, Japan.
- Department of Gastroenterology, Handa City Hospital, Handa, Japan.
- Department of Gastroenterology, Daido Hospital, Nagoya, Japan.
ORCID-Profile: Yosuke Inukai, Masatoshi Ishigami, Hiroki Kawashima
Zitieren
APA
Inukai, Y., Ito, T., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shimizu, T., Hattori, M., Takeyama, T., Ando, Y., Nishikawa, T., Morita, K., Toyoda, H., Ishigami, M., & Kawashima, H. (2024). Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13325
Vancouver
Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, et al. Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13325
BibTeX
@article{Inukai2024,
author = {Inukai, Yosuke and Ito, Takanori and Yokoyama, Shinya and Yamamoto, Kenta and Imai, Norihiro and Ishizu, Yoji and Honda, Takashi and Shimizu, Tatsuji and Hattori, Masashi and Takeyama, Tomoaki and Ando, Yusuke and Nishikawa, Takahiro and Morita, Kiyoshi and Toyoda, Hidenori and Ishigami, Masatoshi and Kawashima, Hiroki},
title = {Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13325}
}
EUVIMED